サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541546

リポソームドキソルビシン市場レポート：製品・用途・地域別、2024～2032年

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 136 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
リポソームドキソルビシン市場レポート：製品・用途・地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のリポソームドキソルビシン市場規模は2023年に13億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて5.1%の成長率（CAGR）を示し、2032年には20億米ドルに達すると予測しています。

リポソームドキソルビシンは、さまざまな自己免疫疾患や肝臓、乳房、子宮内膜、胃、腎臓のがんの治療に用いられる化学療法薬です。体内のがん細胞の増殖を止めたり遅らせたりすることで機能します。この薬剤はペグ化リポソームの脂肪で包まれ、注射によって静脈内に投与されます。ドキソルビシンという薬剤は、がん細胞が分裂・増殖するのに必要な酵素をブロックし、リポソームによって薬剤が血流に長く留まり、がん細胞に到達して効果を高める。薬の投与量は、患者の体重、身長、一般的な健康状態によって異なります。従来から使用されている薬剤と比較して、リポソームドキソルビシンは毒性、骨髄抑制、脱毛症、吐き気が少ないです。

リポソームドキソルビシン市場傾向

骨肉腫、多発性骨髄腫、卵巣がん、自己免疫不全症候群（AIDS）関連カポジ肉腫などの慢性疾患の世界の有病率の増加は、市場成長を促進する主要要因の1つです。これは、労働人口の大多数が座りがちなライフスタイルと多忙なスケジュールを送っていることに起因しており、その結果、これらの疾患の発生が著しく増加し、リポソームドキソルビシン医薬品の需要にプラスの影響を与えています。さらに、がんの治療法に関する大衆の意識の高まりが、市場の成長を後押ししています。パラダイムナノドラッグや改良型化学療法剤の開発など、さまざまな進歩が他の成長促進要因として作用しています。これらの技術革新は、体内での薬剤の部位特異的デリバリーや放出制御を容易にします。その他の要因としては、特に新興経済諸国における医療インフラの大幅な改善、腫瘍学セグメントにおける広範な研究開発（R&D）活動などが挙げられ、市場の成長を後押しすると予想されます。

本レポートで扱う主要質問

  • 世界のリポソームドキソルビシン市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19が世界のリポソームドキソルビシン市場に与えた影響は？
  • 主要地域市場とは？
  • 製品別の市場内訳は？
  • 用途別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のリポソームドキソルビシン市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のリポソームドキソルビシン市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • ドキシル/カエリクス
  • リポドックス
  • ミオセット
  • その他

第7章 市場内訳：用途別

  • 白血病
  • 骨肉腫
  • 乳がん
  • 子宮内膜がん
  • 腎臓がん
  • 多発性骨髄腫
  • カポジ肉腫
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Baxter International Inc.
    • Cipla Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd
    • TTY Biopharm Company Limited
    • Zydus Cadila
図表

List of Figures

  • Figure 1: Global: Liposomal Doxorubicin Market: Major Drivers and Challenges
  • Figure 2: Global: Liposomal Doxorubicin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Liposomal Doxorubicin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Liposomal Doxorubicin Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Liposomal Doxorubicin Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Liposomal Doxorubicin Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Liposomal Doxorubicin (Lipodox) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Liposomal Doxorubicin (Lipodox) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Liposomal Doxorubicin (Myocet) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Liposomal Doxorubicin (Myocet) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Liposomal Doxorubicin (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Liposomal Doxorubicin (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Liposomal Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Liposomal Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Liposomal Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Liposomal Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Liposomal Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Liposomal Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Liposomal Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Liposomal Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Liposomal Doxorubicin (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Liposomal Doxorubicin (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Liposomal Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Liposomal Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Liposomal Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Liposomal Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia-Pacific: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia-Pacific: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: Liposomal Doxorubicin Market: Breakup by Country (in %), 2023
  • Figure 79: Middle East and Africa: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Liposomal Doxorubicin Industry: SWOT Analysis
  • Figure 81: Global: Liposomal Doxorubicin Industry: Value Chain Analysis
  • Figure 82: Global: Liposomal Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liposomal Doxorubicin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Liposomal Doxorubicin Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Liposomal Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Liposomal Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Liposomal Doxorubicin Market: Competitive Structure
  • Table 6: Global: Liposomal Doxorubicin Market: Key Players
目次
Product Code: SR112024A3921

The global liposomal doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.

Liposomal Doxorubicin Market Trends:

The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global liposomal doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.

Breakup by Product:

Doxil/Caelyx

Lipodox

Myocet

Others

Breakup by Application:

Leukemia

Bone Sarcoma

Breast Cancer

Endometrial Cancer

Kidney Cancer

Multiple Myeloma

Kaposi Sarcoma

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.

Key Questions Answered in This Report:

  • How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global liposomal doxorubicin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global liposomal doxorubicin market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liposomal Doxorubicin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Doxil/Caelyx
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lipodox
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Myocet
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Leukemia
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bone Sarcoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Breast Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endometrial Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Multiple Myeloma
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Kaposi Sarcoma
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Baxter International Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Cipla Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Johnson & Johnson
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Merck KGaA
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Pfizer Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Sun Pharmaceutical Industries Ltd
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Teva Pharmaceutical Industries Ltd
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 TTY Biopharm Company Limited
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Zydus Cadila
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio